The United States market has been flat over the last week but has seen a significant rise of 30% over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying growth companies with high insider ownership can be crucial for investors seeking to align their interests with company insiders who have a vested interest in long-term success.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	35.7%	74.1%
Upstart Holdings (UPST)	12.8%	53.6%
Precigen (PGEN)	11.9%	68.4%
Karman Holdings (KRMN)	17%	53.2%
Enovix (ENVX)	12.4%	41.1%
Clene (CLNN)	12%	62.2%
Caledonia Mining (CMCL)	14.3%	29.2%
Better Home & Finance Holding (BETR)	19.3%	104%
Astera Labs (ALAB)	10.8%	27.8%
AppLovin (APP)	27.4%	22.1%

Here's a peek at a few of the choices from the screener.

Corcept Therapeutics (CORT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of approximately $5 billion.

Operations: The company's revenue is primarily generated from the discovery, development, and commercialization of pharmaceutical products, amounting to $761.41 million.

Insider Ownership: 11.8%

Revenue Growth Forecast: 18.9% p.a.

Corcept Therapeutics exhibits strong insider ownership with substantial insider buying over the past three months, indicating confidence in its growth trajectory. The company recently achieved FDA approval for Lifyorli, enhancing its oncology portfolio and positioning it as a key player in treating platinum-resistant ovarian cancer. Despite lower profit margins compared to last year, Corcept's earnings are forecasted to grow significantly at 45.6% annually, outpacing both revenue growth and the broader US market expectations.

BillionToOne (BLLN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: BillionToOne, Inc. is a precision diagnostics company that focuses on quantifying biology to develop molecular diagnostics, with a market cap of $3.99 billion.

Operations: The company generates revenue of $305.11 million from its Medical Labs & Research segment.

Insider Ownership: 11.1%

Revenue Growth Forecast: 20.4% p.a.

BillionToOne's significant insider ownership aligns with its robust growth prospects, as evidenced by its recent inclusion in the S&P Global BMI Index. The company's revenue is forecast to grow over 20% annually, outpacing the US market. Despite a volatile share price, BillionToOne achieved profitability this year and raised its 2026 earnings outlook. Recent product launches in liquid biopsy and non-invasive prenatal testing enhance its competitive edge, supporting substantial revenue growth projections of up to US$445 million for 2026.

Accelerant Holdings (ARX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Accelerant Holdings operates a data-driven risk exchange that links specialty insurance underwriters with risk capital partners and has a market cap of $3.53 billion.

Operations: The company generates revenue through its segments: Underwriting ($393 million), MGA Operations ($240.40 million), and Exchange Services ($330.50 million).

Insider Ownership: 25.4%

Revenue Growth Forecast: 15.8% p.a.

Accelerant Holdings demonstrates strong growth potential with high insider ownership, as evidenced by its forecasted revenue growth of 15.8% per year, surpassing the US market average. Despite recent leadership changes and a reported net loss of US$1.43 billion for 2025, the company is expected to become profitable within three years. The board has approved a share repurchase program worth up to US$200 million, indicating confidence in future performance and aligning with strategic financial management objectives.

Turning Ideas Into Actions

• Explore the 202 names from our Fast Growing US Companies With High Insider Ownership screener here.
• Ready To Venture Into Other Investment Styles? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.